| Revenue growth | 32% YoY growth to INR 110.7 crores in FY26. |
|---|---|
| Margins | EBITDA margins improved to 20.4% due to better product mix. |
| Demand visibility | Strong demand in textile, HPC, and paints/coatings segments. |
| Management confidence | High confidence in sustaining growth through specialty bio-based products. |
Growth
FY26 Revenue INR 110.7cr (+32% YoY); PAT INR 12cr (+62% YoY); EBITDA margins expanded 321bps to 20.4%.
Outlook
Targeting 65% capacity utilization by FY27; aiming for 30-35% export revenue share in 2-3 years.
Risks
Seasonal revenue concentration (55% in H2); geopolitical tensions affecting raw material costs and Bangladesh exports.
Earnings Call filed with NSE, NSE: NEOCHEM. Summary written with AI assistance from the document.
Neochem Bio Solutions Ltd: key numbers
- Share price
- ₹106.20
- Market cap
- ₹181.8 Cr
- Revenue (annual)
- ₹110.7 Cr
- Net profit (annual)
- ₹12.03 Cr
- P/E (TTM)
- 15.1×Sector 37.5×
- Promoter holding
- 66.72%
- FII holding
- 0.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neochem Bio Solutions Ltd
All →Neochem Bio Solutions Annual General Meeting
Neochem Bio Solutions Limited held its 9th Annual General Meeting on September 21, 2026, where management reviewed the company's performance and discussed future business strategies.
Neochem Bio Solutions Promoter Buying: ₹0.14 Cr
Promoter Swapnil R. Makati acquired 1,200 equity shares of Neochem Bio Solutions Limited for ₹0.14 Crore via an on-market purchase.
- Value
- ₹0.14 Cr
- Promoter stake change
- +0.01%
Neochem Bio Solutions Promoter Buying: ₹0.07 Cr
Promoter and MD Swapnil Makati purchased 7,200 Neochem Bio Solutions shares on NSE for ₹0.07 Crore. His stake rose from 54.70% to 54.74%.
- Value
- ₹0.07 Cr
- Promoter stake change
- +0.04%
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions reported FY26 revenue of ₹110.7 Cr (+32% YoY) and PAT of ₹12.0 Cr (+62% YoY), driven by specialty chemical demand and segment diversification into home and personal care.
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions delivered a strong FY26 with 32% revenue growth and 53% EBITDA expansion, driven by a strategic pivot from white-label manufacturing to its own higher-margin specialty brand.
Neochem Bio Solutions Earnings Call: Key Takeaways
Neochem Bio Solutions Limited reported FY26 Total Income of ₹113.4cr, reflecting 32% YoY growth. Strategy focuses on diversifying from textile into HPC and industrial specialty chemicals.